71.9 years, SD=12.3) were identified between 2000 and 2008. The median length of statin use in cases and controls prior to diagnosis or index date was 3.9 years (IQR 2.3–6.1 years). Analysis by histological subtype showed an inverse association for OAC (OR 0.61, 95% CI 0.39 to 0.94) and for OSCC (OR 0.41, 95% CI 0.21 to 0.80). Categorisation into lipophilic and hydrophilic statins demonstrated significant inverse associations for only lipophilic statins for both OAC (OR 0.60, 95% CI 0.38 to 0.95) and OSCC (OR 0.46, 95% CI 0.23 to 0.91). There was a dose-response effect for statins and both OAC and OSCC ($p < 0.05$ for linear trend) comparing high and low-dose statin use.

Conclusion The data supports lipophilic statins having a protective effect against the development of both OAC and OSCC, with evidence of a dose-response trend. Confirmation in other populations is required. Detailed statin use, according to class and dose, should be measured in future aetiological studies of both OAC and OSCC. The information supports assessment of these drugs in chemoprevention of OAC in the general population and those with Barrett's oesophagus in clinical trials.

Competing interests None declared.

PWE-009 **DIETARY DOCOSAHEXAENOIC ACID IS INVERSELY ASSOCIATED WITH THE RISK OF DEVELOPING OESOPHAGEAL ADENOCARCINOMA: A UK PROSPECTIVE STUDY IN THE EPIC-NORFOLK COHORT, USING INFORMATION FROM 7-DAY FOOD DIARIES**

doi:10.1136/gutjnl-2012-302514d.9

^{1,2}L Alexandre, * ^{1,2}M Yates, ³R Luben, ²E Cheong, ²L Igali, ⁴R Fitzgerald, ³K-T Khaw, ^{1,2}A Hart. ¹Norwich Medical School, University of East Anglia, Norwich, UK; ²Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich, UK; ³Strangeways Research Laboratory, University of Cambridge, Cambridge, UK; ⁴Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK

Introduction Dietary docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are both n-3 polyunsaturated fatty acids (n3 PUFAs) which have both anti-inflammatory and anti-carcinogenic actions, including inhibiting angiogenesis and tumour cell proliferation, and promoting apoptosis. The aim of this study was to conduct the first epidemiological investigation to determine if there is an inverse association between DHA and EPA intake and the risk of developing both Barrett's oesophagus (BO) and oesophageal adenocarcinoma (OAC).

Methods A total of 25 639 men and women aged 40–75 years, were recruited between the years 1993 and 1997 into the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort Study. At baseline, participants completed detailed 7-day food diaries which were then coded by nutritionists. Subjects were then followed-up over subsequent years for the development of BO and OAC. A review of case notes confirmed these diagnoses. Dietary intake of n3 PUFAs were compared between cases and a random sample of 3 797 controls in a case-cohort analysis. Intakes were divided into quintiles and both biological gradients and threshold effects were calculated. Cox regression estimated the HR for both DHA and EPA, adjusted for age, gender, BMI, smoking, alcohol, and arachidonic acid intake.

Results During follow-up, 104 patients were diagnosed with BO (80% men, median age 67.0 yrs [IQR 61.1–73.1] at diagnosis) after a median follow-up of 6.2 yrs (IQR 4.1–8.1). A further 63 patients developed OAC (83% men, median age 73.0 yrs [IQR 67.0–78.0] at diagnosis) after a median follow-up of 6.4 yrs (IQR 4.4–8.9). For OAC, there was a large significant inverse association, in a threshold manner, comparing the lowest quintile with a summation of the top four quintiles of dietary intake, for DHA (HR 0.47, 95% CI 0.25 to 0.88, $p = 0.02$). EPA (HR 0.60, 95% CI 0.31 to 1.15, $p = 0.12$) intake

was not significantly associated with OAC. For BO, no significant associations were found with either dietary DHA (HR 0.69, 95% CI 0.40 to 1.20, $p = 0.19$) or EPA (HR 1.03, 95% CI 0.56 to 1.90, $p = 0.93$). No gradient effects across quintiles were seen for either BO or OAC.

Conclusion Dietary DHA was associated with an approximate 50% risk reduction for OAC, although there were no significant effects for BO. The data support a role for dietary DHA in preventing the malignant transformation of BO to OAC, and therefore should be measured in future aetiological studies of OAC.

Competing interests None declared.

PWE-010 **DIETARY CAMPESTEROL IS INVERSELY ASSOCIATED WITH THE RISK OF DEVELOPING OESOPHAGEAL ADENOCARCINOMA: A UK PROSPECTIVE STUDY IN THE EPIC-NORFOLK COHORT, USING INFORMATION FROM 7-DAY FOOD DIARIES**

doi:10.1136/gutjnl-2012-302514d.10

^{1,2}L Alexandre, * ^{1,2}M Yates, ³R Luben, ²E Cheong, ²L Igali, ⁴R Fitzgerald, ³K-T Khaw, ^{1,2}A Hart. ¹Norwich Medical School, University of East Anglia, Norwich, UK; ²Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich, UK; ³Strangeways Research Laboratory, University of Cambridge, Cambridge, UK; ⁴Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK

Introduction Dietary phytosterols (PS), including campesterol, the most bioavailable of this group, are structurally similar to cholesterol, and are present in grain legumes, cereals, nuts and vegetable oils. Experimental studies have shown PS have several anti-carcinogenic effects, including inducing apoptosis and inhibiting both angiogenesis and cell proliferation. The aim of this study was to conduct the first epidemiological investigation to determine if an inverse association exists between PS intake and the risk of both Barrett's oesophagus (BO) and oesophageal adenocarcinoma (OAC).

Methods A total of 25 639 men and women aged 40–75 years, were recruited between the years 1993 and 1997 into the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort Study. At baseline, participants completed detailed 7-day food diaries which were coded by nutritionists. Subjects were followed-up over subsequent years for the development of BO and OAC. A review of case notes confirmed these diagnoses. Dietary intakes were compared between cases and a random sample of 3 797 controls in a case-cohort analysis. Cox regression estimated the HR for both campesterol and total PS.

Results During follow-up, 104 patients were diagnosed with BO (80% men, median age 67.0 yrs [IQR 61.1–73.1] at diagnosis) after a median follow-up of 6.2 yrs (IQR 4.1–8.1). A further 63 patients developed OAC (83% men, median age 73.0 yrs [IQR 67.0–78.0] at diagnosis) after a median follow-up of 6.4 yrs (IQR 4.4–8.9). For BO, no significant associations were found with campesterol (HR 1.47, 95% CI 0.77 to 2.79) or total dietary PS (HR 1.28, 95% CI 0.70 to 2.33), in either sex. For OAC, in men, there were inverse associations with campesterol (HR 0.43, 95% CI 0.22 to 0.83, $p = 0.01$), in a threshold manner, comparing the lowest with a summation of the top four quintiles of intake. In women, for OAC, there were no such associations with campesterol (HR 2.13, 95% CI 0.44 to 10.15, $p = 0.34$). Total PS intake (HR 0.71, 95% CI 0.38 to 1.35) was not significantly associated with OAC in either sex.

Conclusion Campesterol intake was associated with an approximate 55% risk reduction for OAC in men, although there were no significant effects in BO or for either condition in women. The data support a role for dietary campesterol, in preventing the malignant transformation of BO to OAC, and therefore these micronutrients should be measured in future aetiological studies of OAC.

Competing interests None declared.